What are the 2026 ACC (American College of Cardiology)/AHA (American Heart Association) dyslipidemia guidelines for adult lipid management?

2026 ACC/AHA Dyslipidemia Guideline Overview

The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia has been published and replaces the 2018 cholesterol guideline, with updated recommendations on risk assessment, lipid-lowering therapies, and lipoprotein(a) management. 1

Core Framework: Four Statin Benefit Groups

The fundamental approach identifies four groups where statin therapy demonstrably reduces atherosclerotic cardiovascular disease (ASCVD) events 2, 3:

1. Secondary Prevention: Clinical ASCVD

• Age ≤75 years: Initiate high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) unless contraindicated 2, 3
• Age >75 years or safety concerns: Use moderate-intensity statin therapy 2, 3
• Age >75 years without prior statin use: Evaluate potential benefits versus adverse effects and drug interactions before initiating moderate- or high-intensity therapy; continue statins in those already tolerating them 3

2. Severe Hypercholesterolemia: LDL-C ≥190 mg/dL

• Age ≥21 years: Start high-intensity statin therapy immediately—do not wait for genetic testing or detailed family history 4
• Rule out secondary causes first (hypothyroidism, chronic kidney disease, obstructive liver disease) 3, 4
• Target: Achieve at least 50% LDL-C reduction from baseline 3, 4
• If LDL-C remains >100 mg/dL on maximal tolerated statin: Add ezetimibe 4
• For familial hypercholesterolemia with LDL-C ≥100 mg/dL despite statin plus ezetimibe: Consider PCSK9 inhibitor 4
• Critical pitfall: Do not use 10-year ASCVD risk calculators for this group—they are automatically high-risk based on LDL-C alone 4

3. Diabetes: Ages 40-75 Years with LDL-C 70-189 mg/dL

• Standard approach: Initiate moderate-intensity statin therapy 3
• If estimated 10-year ASCVD risk ≥7.5%: Consider high-intensity statin therapy 3
• Ages <40 or >75 years, or LDL-C <70 mg/dL: Evaluate benefits versus risks and patient preferences before initiating or intensifying therapy 3

4. Primary Prevention Without Diabetes: Ages 40-75 Years with LDL-C 70-189 mg/dL

Risk stratification is essential 3:

• Calculate 10-year ASCVD risk using the Pooled Cohort Equations (note: 2026 guidelines will likely incorporate PREVENT equations with lower risk thresholds) 3, 5
• ≥7.5% 10-year risk: Initiate moderate- to high-intensity statin therapy 3
• 5% to <7.5% 10-year risk: Offer moderate-intensity statin therapy 3
• <5% 10-year risk: Statin therapy may be considered in select individuals 2

Before initiating therapy, engage in clinician-patient discussion about potential benefits, adverse effects, drug interactions, and patient preferences 3

Risk-enhancing factors to consider when decision is uncertain 2, 3:

• LDL-C ≥160 mg/dL
• Family history of premature ASCVD (onset <55 years in male first-degree relative or <65 years in female first-degree relative)
• High-sensitivity CRP ≥2 mg/L
• Coronary artery calcium (CAC) score ≥300 Agatston units (CAC improves risk estimation beyond traditional factors) 5
• Ankle-brachial index <0.9

Key 2026 Updates

Risk Assessment Evolution

• PREVENT equations will replace Pooled Cohort Equations, establishing lower risk thresholds for treatment 5
• Coronary artery calcium scoring increasingly emphasized to refine medication allocation and LDL-C goals 5
• Universal lipoprotein(a) assessment recommended at least once in adulthood for risk classification 6, 7

Treatment Intensification Strategies

• Acute coronary syndrome: Immediate initiation of high-intensity statin plus ezetimibe for most patients, moving away from sequential strategies to ensure early LDL-C goal attainment 6, 7
• Combination therapy: For high-risk individuals, consider upfront combination of low/moderate-intensity statin with ezetimibe or bempedoic acid 5
• Very-high risk patients: Treatment to LDL-C <30 mg/dL further reduces ASCVD risk without significant adverse events 5
• PCSK9 inhibitors: Prioritize for patients with elevated lipoprotein(a), who may experience greater ASCVD risk reduction 5

Expanded Pharmacologic Arsenal

New lipid-lowering options include bempedoic acid, evinacumab, inclisiran, and icosapent ethyl (EPA alone, not EPA/DHA mixtures) 6, 7

Statin Intensity Definitions

High-intensity (≥50% LDL-C reduction) 3:

• Atorvastatin 40-80 mg
• Rosuvastatin 20-40 mg

Moderate-intensity (30% to <50% LDL-C reduction) 3:

• Atorvastatin 10-20 mg
• Rosuvastatin 5-10 mg
• Simvastatin 20-40 mg
• Pravastatin 40-80 mg
• Lovastatin 40 mg
• Fluvastatin 80 mg
• Pitavastatin 1-4 mg

What This Guideline Does NOT Recommend

• No specific LDL-C or non-HDL-C targets for primary or secondary prevention—focus is on statin intensity rather than titration to specific goals 3
• No recommendations for initiating or discontinuing statins in NYHA class II-IV ischemic systolic heart failure or maintenance hemodialysis patients 3
• No routine use of nonstatin drugs combined with statins for ASCVD event reduction, except in specific high-risk scenarios 3

Critical Implementation Points

Lifestyle counseling remains the foundation at initial and follow-up visits 3

Monitoring: Reassess lipid response within 4-12 weeks after initiation 4

Adherence: Re-emphasize lifestyle changes and statin adherence before adding nonstatin therapy 3

Sex and racial considerations: Treatment decisions should be based on ASCVD risk level, not LDL-C alone, to avoid overtreatment of lower-risk groups (e.g., younger white women) and undertreatment of higher-risk groups (e.g., African American individuals) 3